MedTrace Logo

Immuno 1: Immune Reconstitution Following Conventional or High-Dose Chemotherapy With Stem Cell Transplant

NCT00231712 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2006-08-23

No results posted yet for this study

Summary

The purpose of this study is to conduct an analysis of the influences of

1. conventional chemotherapy
2. high-dose chemotherapy followed by autologous stem cell transplant
3. high-dose chemotherapy followed by allogeneic stem cell transplant on the recovery of the immune system.

Detailed analysis will help to better understand the pathways of recovery of the immune system following chemotherapy as well as the pathways of recovery of the immune system following autologous or allogeneic stem cell transplantation.

Conditions

Sponsors & Collaborators

  • University of Wuerzburg

    collaborator OTHER

  • Julius-Maximilians University

    lead OTHER

Principal Investigators

  • Paul G Schlegel, MD · University Children's Hospital Pediatric Oncology Wuerzburg / Germany

  • Matthias Eyrich, MD · Pediatric Stem Cell Transplant Program

Eligibility

Min Age
0 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Completion
2009-02-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00231712 on ClinicalTrials.gov